R.grid, London (2026)

18/05/2026

𝗢𝘃𝗲𝗿 𝟰𝟬 𝘆𝗲𝗮𝗿𝘀 𝗮𝗳𝘁𝗲𝗿 𝗛𝗜𝗩/𝗔𝗜𝗗𝗦 𝘄𝗮𝘀 𝗳𝗶𝗿𝘀𝘁 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗲𝗱, 𝘄𝗲 𝘀𝘁𝗶𝗹𝗹 𝗱𝗼𝗻’𝘁 𝗵𝗮𝘃𝗲 𝗮 𝘃𝗮𝗰𝗰𝗶𝗻𝗲.

More than 40.8 million people worldwide are living with HIV/AIDS, and approximately 630,000 people died from HIV-related causes in 2024 alone. Despite significant progress, 1.3 million people were newly infected last year.

The challenge is scientific and systemic.

Several factors continue to shape why progress has been slower than expected:

• 𝗛𝗶𝗴𝗵𝗹𝘆 𝗲𝘃𝗮𝘀𝗶𝘃𝗲 𝘃𝗶𝗿𝘂𝘀: HIV mutates rapidly, exists in many strains, and targets the immune cells vaccines rely on.
• 𝗡𝗼 𝗻𝗮𝘁𝘂𝗿𝗮𝗹 𝗶𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝗺𝗼𝗱𝗲𝗹: there are no documented cases of immune clearance to replicate.
• 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗰𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝘆: approaches like broadly neutralising antibodies require multi-step immune training.
• 𝗟𝗼𝗻𝗴, 𝗰𝗼𝗺𝗽𝗹𝗲𝘅 𝘁𝗿𝗶𝗮𝗹𝘀: global, multi-year studies are needed to demonstrate prevention and efficacy.
• 𝗙𝘂𝗻𝗱𝗶𝗻𝗴 𝘃𝗼𝗹𝗮𝘁𝗶𝗹𝗶𝘁𝘆: investment often shifts with political and global health priorities.
• 𝗨𝗻𝗲𝘃𝗲𝗻 𝘁𝗿𝗶𝗮𝗹 𝗶𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲: high-burden regions remain under-resourced for large-scale research.
• 𝗧𝗿𝘂𝘀𝘁 𝗴𝗮𝗽𝘀 𝗮𝗻𝗱 𝘀𝘁𝗶𝗴𝗺𝗮: shaped by historical exclusion, impacting participation, policy urgency, and public discourse.

These issues directly affect who participates, how trials run, and how quickly progress can be made.

Despite these challenges, there is momentum. Advances in mRNA, antibody-based approaches, and more community-led research models are starting to shift the landscape.

An HIV vaccine remains one of the most complex challenges in global health. Progress will depend on both better science and stronger systems to support it.

14/05/2026

𝗔𝗜 𝘄𝗼𝗻’𝘁 𝗷𝘂𝘀𝘁 𝗳𝗶𝘅 𝗯𝗿𝗼𝗸𝗲𝗻 𝘁𝗿𝗶𝗮𝗹 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀. 𝗜𝘁 𝘄𝗶𝗹𝗹 𝗲𝘅𝗽𝗼𝘀𝗲 𝘁𝗵𝗲𝗺.

We’re heading to Scope Summit Boston on May 18-19! 🇺🇸 Visit us at 📍 Booth 19

At Scope X, the conversation moves beyond what AI can do to what actually works in real trial delivery.

Delays in clinical trials are driven by fragmented systems, manual workflows, and processes that don’t scale.

AI makes that visible.

The shift now is toward rebuilding trial operations with AI-native infrastructure - removing manual work across the study lifecycle and supporting how trials actually run.

For sponsors, CROs, and research teams, that means faster timelines, lower costs, and less admin.

📍 Booth 19

If you’re there, come find us. We’re having practical conversations about what’s slowing trials down, and what it takes to move them forward.

12/05/2026

𝗧𝗵𝗲 𝗯𝗶𝗴𝗴𝗲𝘀𝘁 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝘀 𝗶𝗻 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗮𝗿𝗲 𝗶𝗻 𝗵𝗼𝘄 𝗰𝗮𝗿𝗲 𝗶𝘀 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝗲𝗱.

Today is International Nurses Day.

Through our work with research nurses, it's clear that a significant share of time is lost to the systems around care rather than care itself. Manual data entry, paper-based workflows, and fragmented tools continue to absorb hours that could otherwise be spent with patients.

R.grid supported the automation of paper-based data entry using ML-powered data processing to accurately digitize patient assessment responses and free-text answers at scale:
• 𝗗𝗮𝘁𝗮 𝗲𝗻𝘁𝗿𝘆 𝘁𝗶𝗺𝗲 𝘄𝗮𝘀 𝗿𝗲𝗱𝘂𝗰𝗲𝗱 from up to 2 days per patient visit to ~20 seconds.
• 𝗗𝗮𝘁𝗮 𝗹𝗼𝗴𝗴𝗶𝗻𝗴 𝗰𝗼𝘀𝘁𝘀 𝗱𝗲𝗰𝗿𝗲𝗮𝘀𝗲𝗱 from around ~$2,000 to ~$0.42 per visit.
• Tasks that previously required days of effort each week were 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝗱 𝗶𝗻 𝘀𝗲𝗰𝗼𝗻𝗱𝘀.

These gains have broader implications on efficiency. With nearly 29 million nurses globally and a shortage of around 6 million, reducing administrative burden is critical to preserving clinical capacity where it is needed most.

Supporting the nursing workforce is not only about capacity, but about designing systems that return time to care.

05/05/2026

𝗔𝘀𝘁𝗵𝗺𝗮 𝗶𝘀 𝘁𝗿𝗲𝗮𝘁𝗮𝗯𝗹𝗲. 𝗦𝗼 𝘄𝗵𝘆 𝗱𝗼𝗲𝘀 𝗶𝘁 𝘀𝘁𝗶𝗹𝗹 𝗰𝗼𝘀𝘁 𝗵𝘂𝗻𝗱𝗿𝗲𝗱𝘀 𝗼𝗳 𝘁𝗵𝗼𝘂𝘀𝗮𝗻𝗱𝘀 𝗼𝗳 𝗹𝗶𝘃𝗲𝘀 𝗲𝗮𝗰𝗵 𝘆𝗲𝗮𝗿?

Today is World Asthma Day - a reminder that for many people, managing asthma is far from simple.

Around 262 million people live with asthma globally. It leads to approximately 455,000 deaths each year, with most occurring in low and middle income countries.

The reasons are often practical, not clinical.
• 𝗘𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹 𝗶𝗻𝗵𝗮𝗹𝗲𝗿𝘀 𝗮𝗿𝗲 𝘁𝗼𝗼 𝗲𝘅𝗽𝗲𝗻𝘀𝗶𝘃𝗲 or not available
• 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀 𝗶𝘀 𝗱𝗲𝗹𝗮𝘆𝗲𝗱 due to limited access to testing and specialists
• 𝗔𝗶𝗿 𝗽𝗼𝗹𝗹𝘂𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁𝗮𝗹 𝗲𝘅𝗽𝗼𝘀𝘂𝗿𝗲𝘀 worsen symptoms on a daily basis
• 𝗢𝗻𝗴𝗼𝗶𝗻𝗴 𝗰𝗮𝗿𝗲 𝗶𝘀 𝗱𝗶𝗳𝗳𝗶𝗰𝘂𝗹𝘁 𝘁𝗼 𝗺𝗮𝗶𝗻𝘁𝗮𝗶𝗻, leading to reliance on emergency treatment

These challenges mean symptoms go unmanaged for long periods, increasing the risk of severe and preventable attacks.

Research is improving what care can look like:
• 𝗡𝗲𝘄 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝗰 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 like Tezepelumab are reducing asthma attacks in severe cases
• 𝗟𝗼𝗻𝗴𝗲𝗿-𝗮𝗰𝘁𝗶𝗻𝗴 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 such as Depemokimab are being developed to make treatment easier to follow
• 𝗖𝗼𝗺𝗯𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝗵𝗮𝗹𝗲𝗿𝘀 from the MANDALA trial pair a bronchodilator with an anti-inflammatory to treat symptoms and reduce flare-ups
• 𝗧𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 like Dupilumab and Benralizumab focus on specific immune drivers, enabling more tailored treatment.

Progress is happening, but it is not reaching everyone equally.

Improving outcomes globally means expanding access to diagnosis, treatment, and long-term care, alongside continued advances in research.

01/05/2026

𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗶𝘀 𝗺𝗲𝗮𝗻𝘁 𝘁𝗼 𝘀𝗲𝗿𝘃𝗲 𝗲𝘃𝗲𝗿𝘆𝗼𝗻𝗲, 𝗯𝘂𝘁 𝗻𝗼𝘁 𝗲𝘃𝗲𝗿𝘆𝗼𝗻𝗲 𝗰𝗮𝗻 𝗮𝗳𝗳𝗼𝗿𝗱 𝘁𝗼 𝘁𝗮𝗸𝗲 𝗽𝗮𝗿𝘁.

At Research Grid, building a truly representative community network means partnering with organizations who understand the realities people face every day.

UK-based Change Ahead CIC works closely with communities facing complex challenges, including mental health conditions, homelessness, and financial hardship, sharing lived experiences often missing from research conversations.

Through partnerships like this, we help ensure they are reflected in research.

We spoke with Mohsin Ravjani, Founder and CEO of Change Ahead, about the realities facing these communities.

For many, financial compensation is a deciding factor. Without it, taking part simply isn’t possible.

Alongside this, research must be communicated in a way that feels relevant and designed to be accessible. As the industry focuses more on equity, diversity and inclusion, these factors are key to ensuring no one is left behind.

𝗠𝗼𝗿𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗼𝘂𝗿 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻 𝗰𝗼𝗺𝗶𝗻𝗴 𝘀𝗼𝗼𝗻.

17/04/2026

𝗪𝗵𝗮𝘁 𝗶𝗳 𝗮 𝘀𝗶𝗻𝗴𝗹𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗰𝗼𝘂𝗹𝗱 𝗿𝗲𝗽𝗹𝗮𝗰𝗲 𝗮 𝗹𝗶𝗳𝗲𝘁𝗶𝗺𝗲 𝗼𝗳 𝗶𝗻𝗷𝗲𝗰𝘁𝗶𝗼𝗻𝘀?

For many people with haemophilia, managing bleeding is a daily reality, but that could be changing.

Haemophilia is a rare genetic condition where the blood does not clot properly, leading to prolonged bleeding. It affects around 400,000 people worldwide, yet 75% still lack access to adequate care.

New research is targeting some of the biggest challenges people face:
• 𝗥𝗲𝗱𝘂𝗰𝗶𝗻𝗴 𝗳𝗿𝗲𝗾𝘂𝗲𝗻𝘁 𝗯𝗹𝗲𝗲𝗱𝗶𝗻𝗴: RNA-based therapies like fitusiran and anti-TFPI treatments such as marstacimab aim to lower bleeding rates.
• 𝗥𝗲𝗱𝘂𝗰𝗶𝗻𝗴 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗯𝘂𝗿𝗱𝗲𝗻: Once-weekly and longer-acting approaches are moving away from frequent injections.
• 𝗜𝗺𝗽𝗿𝗼𝘃𝗶𝗻𝗴 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀: Gene therapies, including those studied in HOPE-B and AFFINE trials, are exploring sustained clotting factor production after a single treatment.

Together, these advances could mean fewer risks and more freedom in everyday life.

Progress like this doesn’t happen in labs alone. Organizations in our network like The Haemophilia Society UK and Hemophilia Alliance are helping raise awareness, support patients, and push for better access to care.

At Research Grid, we see how important it is to bring lived experience into research, helping ensure these advances translate into something meaningful.

We’re excited for a future shaped by people living with haemophilia, and the progress making it possible.

14/04/2026

𝗪𝗵𝗮𝘁 𝗶𝘀 𝗦𝗷𝗼𝗴𝗿𝗲𝗻’𝘀 𝘀𝘆𝗻𝗱𝗿𝗼𝗺𝗲 𝗮𝗻𝗱 𝘄𝗵𝘆 𝗶𝘀 𝗶𝘁 𝘀𝘁𝗶𝗹𝗹 𝘁𝗮𝗸𝗶𝗻𝗴 𝘁𝗮𝗸𝗶𝗻𝗴 𝘆𝗲𝗮𝗿𝘀 𝘁𝗼 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗲?

April is Sjögren’s Awareness Month, but awareness hasn’t yet translated into timely diagnosis for many people.

• Sjögren’s is often reduced to dry eyes and mouth, but it’s is far more complex immune-mediated disease affecting up to 4 million people.
• Fatigue, joint pain, and systemic symptoms mean many people go years without answers.

At Research Grid, we partner with communities who understand these struggles.

Today we’re highlighting Sjögren's India In an India-based, patient-led community raising awareness of Sjögren’s syndrome and amplifying the realities people face living with it.

In India, research suggests limited awareness and stigma around invisible illness mean many remain undiagnosed.

Working with community partners like Sjogren’s India helps bring these experiences into clinical research and GP Practices, ensuring research, health and care better reflects the people it’s meant to serve.

Our community network is free for community groups to join. To find out more, feel free to reach out to us at [email protected].

More insights from our conversation with Sjogren's India on our instagram and Youtube coming soon!

09/04/2026

𝗥𝗲𝗰𝗿𝘂𝗶𝘁𝗺𝗲𝗻𝘁 𝗶𝘀 𝘀𝘁𝗶𝗹𝗹 𝗼𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗯𝗶𝗴𝗴𝗲𝘀𝘁 𝗿𝗲𝗮𝘀𝗼𝗻𝘀 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝗳𝗮𝗶𝗹.

80–85% of trials miss enrollment projections, and nearly 30% of sites enroll no participants.

This isn’t just a delivery problem, it’s how recruitment is set up.

Most strategies are built around reach and scale, using broad digital campaigns and large patient databases to maximize volume. It creates visibility, but not always trust.

In practice, this often means:
• Wide reach, low context
• Volume over relevance
• Awareness first, trust later

These participation gaps show up in who takes part, who drops off, and who is never reached.

Much of this comes down to trust. People are more likely to engage when research is introduced through networks they already recognize and that reflect their day-to-day reality.

Community-based approaches shift this.

Trusted networks bring immediate credibility, instead of trying to build trust at the point of enrolment.

As Sam Meyer on our team points out, both researchers and community partners see the same issue: trust isn’t there early enough.

When community partners come first, outcomes change.

In practice, that’s driven a 145% increase in patient engagement, alongside stronger participation, better retention, and more representative data.

03/04/2026

𝗧𝗼𝗽 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗦𝘁𝗼𝗿𝗶𝗲𝘀 𝗳𝗿𝗼𝗺 𝗤1 𝟮𝟬𝟮𝟲

Clinical research has moved quickly in the first quarter of 2026 as regulation, investment and trial results are all shifting the pace.

🇬🇧 𝗜𝗻 𝘁𝗵𝗲 𝗨𝗞, 𝗠𝗛𝗥𝗔 𝗿𝗲𝗳𝗼𝗿𝗺𝘀 𝗮𝗿𝗲 𝘀𝗽𝗲𝗲𝗱𝗶𝗻𝗴 𝘂𝗽 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹𝘀 𝗮𝗻𝗱 𝘀𝗶𝗺𝗽𝗹𝗶𝗳𝘆𝗶𝗻𝗴 𝗽𝗿𝗼𝗰𝗲𝘀𝘀𝗲𝘀.
New routes are being developed for lower-risk studies. Early-stage cell and gene therapy trials are also increasing, strengthening the UK’s role in advanced therapies.

🇪🇺 𝗔𝗰𝗿𝗼𝘀𝘀 𝗘𝘂𝗿𝗼𝗽𝗲, 𝘁𝗵𝗲 𝗳𝗼𝗰𝘂𝘀 𝗶𝘀 𝗼𝗻 𝗴𝗿𝗼𝘄𝘁𝗵 𝗮𝗻𝗱 𝗰𝗼𝗼𝗿𝗱𝗶𝗻𝗮𝘁𝗶𝗼𝗻.
Clinical research continues to contribute significantly to jobs and the economy, while programs like ACT-EU are improving how trials are run across countries.

🇺🇸 𝗜𝗻 𝘁𝗵𝗲 𝗨𝗦, 𝗹𝗮𝘁𝗲-𝘀𝘁𝗮𝗴𝗲 𝘁𝗿𝗶𝗮𝗹𝘀 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁 𝘀𝘁𝗿𝗼𝗻𝗴 𝗺𝗼𝗺𝗲𝗻𝘁𝘂𝗺, 𝘄𝗶𝘁𝗵 𝗮 𝗽𝘀𝗼𝗿𝗶𝗮𝘀𝗶𝘀 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝗶𝗻𝗴 𝗺𝗲𝗮𝗻𝗶𝗻𝗴𝗳𝘂𝗹 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗺𝗲𝗻𝘁𝘀.

The FDA has allowed a paused gene-editing trial to restart, maintaining a focus on safety. A Lyme disease vaccine is advancing, though measuring effectiveness remains complex.

🇯🇵 𝗜𝗻 𝗝𝗮𝗽𝗮𝗻 𝗮𝗻𝗱 𝗮𝗰𝗿𝗼𝘀𝘀 𝗔𝘀𝗶𝗮, 𝗿𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗶𝘀 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀𝗶𝗻𝗴, 𝘄𝗶𝘁𝗵 𝗶𝗣𝗦 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝘀𝗵𝗼𝘄𝗶𝗻𝗴 𝗲𝗮𝗿𝗹𝘆 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘂𝘀𝗲 𝗶𝗻 𝗣𝗮𝗿𝗸𝗶𝗻𝘀𝗼𝗻’𝘀 𝗮𝗻𝗱 𝗵𝗲𝗮𝗿𝘁 𝗳𝗮𝗶𝗹𝘂𝗿𝗲.

Investment across Asia, including Korea, is strengthening the region’s role as a global hub in clinical research.

🧪 𝗚𝗹𝗼𝗯𝗮𝗹𝗹𝘆, 𝗿𝗲𝗰𝗲𝗻𝘁 𝘁𝗿𝗶𝗮𝗹 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗿𝗲𝗳𝗹𝗲𝗰𝘁 𝗯𝗼𝘁𝗵 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝗮𝗻𝗱 𝗿𝗶𝘀𝗸.

Positive signals in chronic hepatitis B sit alongside setbacks in oncology, while upcoming neurological readouts, including Alzheimer’s, are expected to shape what comes next.

At the same time, key challenges remain. Trial timelines are still long, and recruitment, particularly in rare disease research, continues to be a barrier.

Clinical research is evolving, but delivery still depends on how well speed, design and recruitment come together.
Your document has finished loading

02/04/2026

𝗔𝘂𝘁𝗶𝘀𝗺 𝗶𝘀 𝗰𝗼𝗺𝗺𝗼𝗻 (𝟭 𝗶𝗻 𝟭𝟮𝟳 𝗽𝗲𝗼𝗽𝗹𝗲), 𝗯𝘂𝘁 𝗲𝗾𝘂𝗶𝘁𝗮𝗯𝗹𝗲 𝗮𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀 𝗮𝗻𝗱 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝗶𝘀𝗻’𝘁.

🌍 This World Autism Awareness Day, we’re spotlighting the research aiming to change that.

Autism is a neurodevelopmental condition, affecting communication, behavior, and social interaction. Around one third of autistic individuals also have an intellectual disability, and many experience co-occurring conditions such as anxiety, ADHD, epilepsy, and sleep disorders.

A growing body of research is exploring new, evidence-based approaches to better support autistic people, including:

• 𝗢𝗿𝗮𝗹 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝗳𝗼𝗿 𝘀𝗼𝗰𝗶𝗮𝗹 𝗳𝘂𝗻𝗰𝘁𝗶𝗼𝗻𝗶𝗻𝗴: Oral therapies, Arbaclofen (AIMS-2-CT-01) and Balovaptan to improve social functioning, adaptive behavior, and social motivation/interaction, while other emerging therapies (e.g., ART-501) aim to reduce irritability and hyperactivity.
• 𝗡𝗮𝘀𝗮𝗹 𝘀𝗽𝗿𝗮𝘆 𝗳𝗼𝗿 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗲𝗺𝗼𝘁𝗶𝗼𝗻: Intranasal oxytocin, a hormone-based treatment being explored for its effects on social communication and emotional recognition.
• 𝗦𝘁𝗲𝗺 𝗰𝗲𝗹𝗹𝘀 𝗳𝗼𝗿 𝘀𝗼𝗰𝗶𝗮𝗹 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗺𝗲𝗻𝘁𝘀: Cord blood stem cell therapy using cells collected at birth to explore improvements in communication, attention, and behavior.

In addition to this research, progress is championed by our community partners, including Autism Society of America and Children's of Alabama, who continue to drive important work in advocacy, care, and support.

On World Autism Awareness Day, increasing understanding, supporting inclusion, and advancing research remain essential to improving outcomes and opportunities for autistic people and their families.

21/03/2026

𝟭 𝗶𝗻 𝗲𝘃𝗲𝗿𝘆 𝟳𝟬𝟬 𝗰𝗵𝗶𝗹𝗱𝗿𝗲𝗻 𝗯𝗼𝗿𝗻 𝘄𝗼𝗿𝗹𝗱𝘄𝗶𝗱𝗲 𝘄𝗶𝗹𝗹 𝗵𝗮𝘃𝗲 𝗗𝗼𝘄𝗻 𝗦𝘆𝗻𝗱𝗿𝗼𝗺𝗲 (1 in 377 births in the UK). It’s the most common genetic chromosomal condition that causes intellectual disability in the world.

A growing number of studies reflect the global effort to translate genetic and biological insights into meaningful clinical advances for people with Down Syndrome.
Current clinical trials include:
• 𝗔𝗜 𝘁𝗼 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝘁𝗲𝘀𝘁𝗶𝗻𝗴: World first AI trial to improve accuracy of Down’s syndrome test at Royal Bolton’s labs
• 𝗚𝗲𝗻𝗲𝘁𝗶𝗰 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵: mapping genetic drivers of Down Syndrome at Imperial College London
• 𝗜𝗺𝗺𝘂𝗻𝗲 𝗽𝗮𝘁𝗵𝘄𝗮𝘆 𝘁𝗵𝗲𝗿𝗮𝗽𝘆: JAK inhibitor trials studying treatments for autoimmune and inflammatory conditions common in Down syndrome
• 𝗖𝗼𝗴𝗻𝗶𝘁𝗶𝘃𝗲 𝗮𝗻𝗱 𝗯𝗲𝗵𝗮𝘃𝗶𝗼𝗿𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵: clinical trials testing medications and cognitive interventions to improve attention and executive function

On , advancing research, fostering inclusion, and investment in care will improve health outcomes, quality of life, and opportunities for people with Down Syndrome.

R.grid

18/05/2026

14/05/2026

12/05/2026

05/05/2026

01/05/2026

17/04/2026

14/04/2026

09/04/2026

03/04/2026

02/04/2026

21/03/2026

Address

Telephone

Website

Alerts

Contact The Business

Shortcuts

Share

Category